The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
30
No.
27
July 02, 2004
- NCI advisors table proposed $186.5 million nanotechnology research program. NCI proposed to fund three to five “centers for cancer nanotechnology excellence,” a coordinating center, and training programs. Board members said they needed more time, information, to make decision. NCI director asked board to “think big” about nanotechnology. Deputy director called nanotechnology program “transformational.”
- Also in this 8-page issue: John Montgomery, a founder of BioCryst Pharmaceuticals and a former member of the President’s Cancer Panel, dead.
- DOD funds $4.2 million gynecologic oncology research program at four institutions.
- June issue of Business & Regulatory Report included.
TCL
Vol.
30
No.
28
July 09, 2004
- FDA seeks support for reorganization of cancer programs, but debate continues.
- In a letter, ASCO reaffirms its views on oncology consolidation at FDA.
- Also in this 8-page issue: NCI advisors approve $15-million set-aside for laboratory testing on “reduced harm” tobacco products.
- Board approves continuation of partnerships between minority institutions and cancer centers for research, training, and outreach.
- Duke recruits Judd Moul as chief of urology.
- Foundation offers funds for mesothelioma research.
- Other NCI funding opportunities listed.
TCL
Vol.
30
No.
29
July 16, 2004
- NCI advisors approve $144 million program for nanotechnology centers, R01 grants, training. Three to five consortia envisioned.
- NCI brings in grantees to explain their work, promise of nanotech, to advisory board.
- Text of concept statement included in this 8-page issue.
- Also: CALGB elects Schilsky to third term as chairman.
- House subcommittee proposes 2.8 percent increase for NIH, NCI.
- Funding opportunities listed.
TCL
Vol.
30
No.
30
July 23, 2004
- FDA to elevate oncology to office level, consolidate most cancer programs. Search planned for oncologist to head new office.
- Also in this 8-page issue: NCI contract will keep Cancer Genetics Network database alive, but center grants will not be recompeted.
- NCI advisors complete terms on board, Appelbaum’s term as BSA chairman ends.
- Funding opportunities listed.
TCL
Vol.
30
No.
31
July 30, 2004
- Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.
- Also in this 8-page issue: Rep. James Greenwood to become president of Biotechnology Industry Association.
- Medicare to cut payments for cancer drugs by 2-8%. ASCO estimates total cut in reimbursement at $500 million.
- Richard Bloch, advocate for patient information services, dead at 78.
- STAR completes enrollment.
- NCI forms pediatric central IRB.
- Funding opportunities listed.
- July issue of Business & Regulatory report (8 additional pages) included.
CCL
Vol.
27
No.
7
July 30, 2004
- Hematologic Malignancies: ASCO Meeting Highlights New Approaches To Treatment
- Studies Test New Agents Offering Relief From Treatment-Related Side Effects
- Oral UFT Equivalent To FULV In Stage II and III Colon Cancer
- Adjuvant Chemo Improves Survival In Early Lung Cancer
- Treat Cancer, But Protect Heart Anderson Cardiologists Warn
- NCI-Approved Clinical Trials
TCL
Vol.
30
No.
32
August 06, 2004
TCL
Vol.
30
No.
33
August 13, 2004
- The Clinical Trials Working Group: NCI panel considers plan to centralize clinical trial review and prioritization. NCI director faults system for duplication, “equivocal results.”
- Blueprint Group co-chairman Mark Ratain says group seeks “the perfect peer review system,” but a member’s email questions the proposal.
- Cooperative group chairman suggest changes to incentive system.